Compare Amphastar Pharmaceuticals Inc (AMPH) vs Autozone Inc (AZO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Autozone Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.54 (market cap $826.08M), while Autozone Inc trades at $3,087.44 (market cap $50.16B). The key difference: Autozone Inc is far larger — about 60.7× Amphastar Pharmaceuticals Inc's market cap, and Autozone Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | AZO | |
|---|---|---|
Market Cap | $826.08M | $50.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $4.35K |
52-Week Low | $16.87 | $2.94K |
Enterprise Value | $1.22B | $62.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
AutoZone (AZO) trades at $3,072.64, up 2.07% today, amid a bearish technical signal but strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. Revenue has grown steadily to $18.94B in 2025, though net income margins are declining. The company continues aggressive share buybacks and international expansion, with a consensus price target of $3,740.
The outlook is cautiously optimistic, driven by buyback programs and commercial momentum, but risks include competitive pressures and margin compression. With 73% of analysts rating it a Buy, the stock offers value if execution aligns with expansion plans, though investors should monitor same-store sales trends and macroeconomic impacts on discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
